Keros Therapeutics

Historical price data

Keros Therapeutics is focused on discovering and developing innovative treatments for patients with serious diseases by modulating the signaling pathways of the TGF-β protein superfamily. The company leverages its deep understanding of TGF-β biology to develop protein therapeutics that aim to correct imbalances in these pathways, which are implicated in hematopoiesis, muscle regeneration, and bone formation. Its pipeline includes multiple investigational candidates targeting conditions like anemia, pulmonary arterial hypertension, and muscle atrophy. Keros has advanced its lead asset into mid-stage clinical trials and has built a robust discovery platform to generate additional novel therapies.

Engineered ligand trap platform designed to selectively modulate signaling pathways of the TGF-β protein superfamily, including activins, GDFs, and BMPs, to treat disorders of blood, muscle, and bone.

2 drugs in pipeline

Total raised: $142M

Keros faces competition from Bristol Myers Squibb's Reblozyl in MDS anemia and numerous vasodilator therapies in PAH. Its differentiation lies in its novel TGF-β ligand trap mechanism targeting specific pathways implicated in disease pathology, aiming for broader efficacy or disease modification.